QUOTE AND NEWS
Forbes  8 hrs ago  Comment 
An exclusive programming format for tonight's Cubs-Mets game on SNY will have limited commercial interruption due to a unique presenting sponsorship deal with CitiBank. Here's how fans get more baseball content while Citi gets to highlight...
GenEng News  Jun 30  Comment 
The biopharma industry was rattled in 2012 when oncologists at Memorial Sloan-Kettering Cancer Center (MSK) refused to prescribe Zaltrap (ziv-aflibercept) for metastatic colorectal cancer due to its initial $11,000-per-month cost. Zaltrap...
The Hindu Business Line  Jun 28  Comment 
Footballer Bhaichung Bhutia has joined the pharmaceutical company Sanofi’s ‘Steps that Count’ initiative to raise awareness on knee osteoarthritis. The initiative encourages patients to...
FiercePharma  Jun 26  Comment 
U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories promise to break out in a big way, and we are not talking just...
FiercePharma  Jun 26  Comment 
One of the episodes that got ex-Sanofi CEO Chris Viehbacher fired was his very public run-in with France's unions when he decided jobs cuts were needed in France to trim costs. Now we will see if his successor can fare any better as Olivier...
FiercePharma  Jun 24  Comment 
The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year, according to a report from data analytics firm GlobalData. Companies such as Novo Nordisk, Sanofi and Merck lead the...
Market Intelligence Center  Jun 24  Comment 
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Sanofi-Aventis (SNY) that includes 4.69% downside protection. Sell one contract of the Aug. '15...
Market Intelligence Center  Jun 23  Comment 
Sanofi-Aventis (SNY) presents a trading opportunity that offers a 3.39% return in just 87 days. A covered call on Sanofi at the $50.00 level expiring on Sep. '15 offers an assigned return rate of 3.39% or 14.23% annualized. This trade offers...
FierceBiotech  Jun 23  Comment 
As CEO of Sanofi, Chris Viehbacher was always an outspoken champion of the innovation that could be found in biotech, even as it remained an elusive goal inside the Big Pharma. He backed up that belief with major partnerships with the likes of...
FiercePharma  Jun 22  Comment 
Early on in the cancer drug pricing debates, doctors at Memorial Sloan Kettering Cancer Center made waves by rejecting a new Sanofi colon cancer drug as too expensive for its benefits. Now, the noted hospital has taken its cost-benefit analysis to...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki